In 2009, following the closing of my private practice in Omaha, NE, I was accused of billing fraud for submitting billing for two sets of nuclear heart images following a single-injection of radioactive isotope.

​

That isotope was given the trade name Sestamibi. Sestamibi was an isotope I had been involved with along with Teboroxime when it was an experimental research drug.

​

At the time I was a Cardiology Fellow and like everyone else, I was told Teboroxime and Sestamibi did not move around (redistribute) once taken up by the heart.

​

This means you have to inject people with TWO doses of these radioactive compounds to get TWO images (stress and rest).

​

In my plea following weeks of trial, I admitted that I had given a single dose of radioactive isotope and billed for two sets of images. There was even a CMS code for such imaging as I admitted to, raising the questions (1) why would CMS have such a billing code of this wasn't possible to do, and (2) why was this information covered up at trial?

[https://www.flemingmethod.com/about]

​

As you will see throughout this website, FMTVDM demonstrated that Big Pharma lied about the isotope not moving around (redistributing) and they made 3-4 times the profit by requiring two injections split apart into different doses.

​

You might ask if, has anyone else ever noticed such a problem with Big Pharma and nuclear isotopes?

​

The answer would be YES.

​

Before the Technetium 99-m (Tc-99m) isotopes (Sestamibi, Teboroxime, Myoview, et cetera) where used, physicians used Thallium-201 (Tl-201). You will see my published research on the comparison of Tl-201 with Teboroxime using quantitative coronary arteriography (QCA) elsewhere in this website ("nuclear imaging" tab).

​

By the time most physicians were using Tl-201 for heart imaging everyone knew Tl-201 moved around (redistributed) following the initial uptake by the heart. But that was not always the case.

​

Originally, Big Pharma told everyone that Tl-201 didn't move around either. That you needed TWO injections of Tl-201. It turns out that wasn't true either.

​

How do we know?

​

In 2024 at the American Society of Nuclear Cardiology (ASNC) Conference, the 23rd Mario Verani Memorial Lecturer award winner, Dr. Vasken Dilsizian shared the story of how it was discovered - not by Big Pharma admission - that Tl-201 redistributed, thus requiring only a single injection of Tl-201 AND NOT TWO.

​

The following video of that presentation by Dr. Dilsizirin, not only shares this information but discusses Dr. Verani and Dr. Gould - both of whom were involved in my training as a Nuclear Cardiologist.